Antibody–drug conjugates (ADCs) is a fast moving class of targeted biotherapeutics that
currently combines the selectivity of monoclonal antibodies with the potency of a payload …

Attaching a cytotoxic “payload” to an antibody to form an antibody–drug conjugate (ADC)
provides a mechanism for selective delivery of the cytotoxic agent to cancer cells via the …

Antibody-drug conjugates (ADCs) represent a promising therapeutic modality for the clinical
management of cancer. The recent approvals of brentuximab vedotin and ado-trastuzumab …

Antibody–drug conjugates (ADCs) are a relatively new class of anticancer agents designed
to merge the selectivity of monoclonal antibodies with cell killing properties of …

Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that
utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the …

An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which
results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously …

Over the past couple of decades, antibody–drug conjugates (ADCs) have revolutionized the
field of cancer chemotherapy. Unlike conventional treatments that damage healthy tissues …

Antibody–drug conjugates (ADCs) are being actively pursued as a treatment option for
cancer following the regulatory approval of brentuximab vedotin (Adcetris) and ado …

Antibody–drug conjugates (ADCs) have a significant impact toward the treatment of cancer,
as evidenced by the clinical activity of the recently approved ADCs, brentuximab vedotin for …

Antibody–drug conjugates (ADCs) are one of the fastest growing classes of oncology
therapeutics. After half a century of research, the approvals of brentuximab vedotin (in 2011) …